• The New Money
  • Posts
  • China Restricts Rare Earths, AI For Clinical Trials, And Ramping Up US Magnet Production

China Restricts Rare Earths, AI For Clinical Trials, And Ramping Up US Magnet Production

The markets and trends that matter, made simple. Discover what’s next.

April 05, 2025

China Is Restricting More Rare Earth Elements

The Chinese government officially restricted the exportation of more rare earth elements to countries around the world, immediately limiting the export of samarium, gadolinium, terbium, scandium and others. China is the single largest producer and exporter of rare earth elements, which have become increasingly important as material inputs for both technology hardware and military applications.

Building The Future Of Clinical Trials With Artificial Intelligence

NetraMark (CSE: AIAI) entered into a new partnership with contract research organization Worldwide Clinical Trials to leverage their artificial intelligence platform for Phase II and Phase III clinical trials. Their proprietary platform NetraAI is capable of sorting through complex datasets to uncover hidden patient subpopulations and identifying important factors that impact the effectiveness of drug targeting.

USA Rare Earth Is Preparing To Ramp Up Domestic Magnet Production

USA Rare Earth (NASDAQ: USAR) officially commissioned its advanced Innovation Lab at their rare earth sintered neo magnet manufacturing facility located in Oklahoma, which aims to become one of the largest facilities of its kind in the United States. Sintered permanent magnets are widely used in electronics, electrical machinery, medical equipment, and in aerospace and defense applications.

The Sprint

The Markets This Week

+37.2% | NetraMark

+5.4% | ASP Isotopes

Looking to connect? Reach out and get in touch.

New here? Join our community of 40,000+ individuals interested in uncovering the world’s most exciting early stage companies.

Disclaimer: The New Money provides background information on early stage companies from publicly available sources. The New Money provides no advice on dealing in securities, is not a financial adviser and does not pretend to be so. This message is meant for information and educational purposes only. The information contained in this email is not to be considered factual or complete. Anybody interested in obtaining financial and other information on companies mentioned is advised to get it direct from the companies, or from their own investment adviser. The New Money does not intend for this information to be used to inform an investment decision. The New Money has been compensated by some of the companies mentioned in this email for awareness campaigns, which affects our ability to be unbiased. The Principals of The New Money may buy or sell shares of the mentioned companies without further notice. This is why we stress that you conduct extensive due diligence as well as seek the advice of your financial advisor or a registered broker-dealer before investing in any securities. The New Money and its principals and agents are not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Always do your own research and consult with a licensed investment professional before making an investment. This communication should not be used as a basis for making any investment. Investing is inherently risky. While a potential for rewards exists, by investing, you are putting yourself at risk. You must be aware of the risks and be willing to accept them in order to invest in any type of security. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy or Sell securities. No representation is being made that any stock trade will or is likely to achieve profits. Comparisons made to other featured companies or past performance is not indicative of future results.